Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
NEW YORK, Jan. 20, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of MannKind Corporation (“MannKind” or the “Company”) (Nasdaq:MNKD) between August 10, 2015 and January 5, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired MannKind securities between August 10, 2015 and January 5, 2016, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
